Wiggin and Dana Advises Premacure Holding AB on the Sale of Premacure AB to Shire plc

March 12, 2013

Stamford - The law firm of Wiggin and Dana LLP assisted its client, Premacure Holding AB, in the sale of its subsidiary, Premacure AB, to Shire plc for undisclosed financial terms. As announced by Shire on March 12, 2013, the "acquisition underscores and expands Shire's commitment to bringing innovative therapies to patients with rare disorders worldwide."

Premacure, which was launched in 2006 by entrepreneurs and internationally recognized neonatology clinicians, is developing a protein replacement therapy for the prevention of retinopathy of prematurity (ROP), a rare and potentially blinding disorder that inflicts primarily premature infants.

"We are thrilled to be able to help our client identify and secure a partner with the resources and commitment to bring a new treatment to market that will potentially change the long-term outlook and prevent some of the lifelong complications for preterm infants with ROP," comments Patti Melick, a partner in the Biotechnology and Life Science Practice Group and lead counsel for Wiggin and Dana.

Other Wiggin and Dana attorneys assisting Premacure included Ann Matthews and Cheryl Wawrzonkiewicz. The Wiggin and Dana team worked closely with lawyers from the Swedish law firm, Advokatfirman Lindahl, and the investment advisors, Hjalmarsson & Partners.

For more than 25 years, attorneys in Wiggin and Dana's multidisciplinary Biotechnology and Life Science Practice Group have been providing integrated services to biotechnology, pharmaceutical, medical device and other health care clients in the United States, Scandinavia and other countries.